Navigation Links
Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening

NOIDA, India, Jan. 21 /PRNewswire/ -- Jubilant Organosys Ltd, headquartered in Noida near New Delhi, announced today that its subsidiary Jubilant Biosys Ltd., based in Bangalore, has developed a next generation screening solution, Legend NGSS(TM), that will further enable the process of high throughput screening, accelerating global drug discovery. The software to be launched in the US and Europe initially, allows scientists to capture, store, and analyze Oracle 9i/10g based screening data with greater flexibility, accuracy and speed.

Legend NGSS(TM) allows users to create rich visualization and interactive analysis reports, including dose-response curves and scatter plot heat maps. The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimized on-the fly curve-fitting techniques.

"This novel screening tool for scientific, pharmaceutical and biotech communities around the world can enhance the productivity of pharmaceutical and biotech research," said Christoph Pittius, PhD, Vice President, Global Business Development, Jubilant Biosys.

"This innovative product demonstrates Jubilant's strategy to develop and provide enabling technologies to accelerate the process of Drug Discovery and Development," he added further.

Legend NGSS(TM) has been developed in collaboration with a leading global pharmaceutical company. It is available worldwide on a subscription basis, which includes comprehensive software support and training. The product has generated substantial interest and response during prelaunch activities from global pharmaceutical companies involved in drug discovery.

About Jubilant Biosys

Jubilant Biosys Ltd. headquartered in Bangalore (, is a subsidiary of India-based Jubilant Organosys Ltd. It provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has 125,000 sq. ft. state-of-the-art facility in Bangalore, India. The center houses more than 500 scientists specializing in Bioinformatics, in vitro, in vivo biology, HTS, medicinal chemistry, structural biology, pharmacology, molecular modeling, information technology, and other scientific disciplines. The company has expanded relationships with the global pharmaceutical industry across the drug discovery and development value chain.

Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, the largest custom research and manufacturing services (CRAMS) and drug discovery and development services company out of India. The Company's consolidated sales in FY '07-08 stood at over US$ 600 million.

SOURCE Jubilant Biosys
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant and BioLeap Announce New Partnership in Drug Discovery
2. SemBioSys announces senior management changes
3. Prosolia and Indigo BioSystems Come Together to Create FireFly(TM) Data Conversion Software for Mass Spectrometers
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
6. SemBioSys begins phase I/II trial of insulin produced in plant seeds
7. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
8. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
9. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
10. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
11. SemBioSys announces second quarter 2008 financial and operational results
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):